Avacen and CellMark Team Up to Market Non-Drug Treatment Device for Fibromyalgia Pain

Avacen and CellMark Team Up to Market Non-Drug Treatment Device for Fibromyalgia Pain
San Diego-based biotech company Avacen Medical and CellMark Medical of Gothenburg, Sweden, have formed a strategic partnership to leverage CellMark’s global network across 120 markets to boost sales and marketing of the Avacen-100 Class-II pain relief medical device. The Avacen-100 recently received the European Union CE (Conformité Européenne) Mark approving it for the treatment of widespread pain associated with fibromyalgia, arthritis, and other conditions by temporarily increasing microcirculation. The device also has FDA approval as muscular relaxation equipment and Health Canada Medical Device License approval. Avacen-100
Subscribe or to access all post and page content.